PMID: 6160343Jan 1, 1981Paper

Cardiovascular effects of a new coronary vasodilator N-(2-hydroxyethyl)nicotinamide nitrate (SG-75): comparison with nitroglycerin and diltiazem

Journal of Cardiovascular Pharmacology
K SakaiH Nabata

Abstract

The cardiovascular effects of a newly developed nicotinamide derivative, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75), were examined in anesthetized, open-chest or closed-chest dogs and compared with those of nitroglycerin and diltiazem. When administered intra-arterially, SG-75 (0.003-1 mg) increased coronary, renal, mesenteric, and femoral blood flows in a dose-dependent fashion, without affecting systemic blood pressure or cardiac function. The coronary vasodilator response to SG-75 was not influenced by intra-arterial administration of propranolol, atropine, diphenhydramine, or dipyridamole. SG-75 (0.03-1 mg/kg) administered intravenously decreased systemic blood pressure and peripheral (coronary, renal, mesenteric, and femoral) vascular resistance and increased peripheral blood flow in a dose-dependent manner. In doses of 0.03-0.3 mg/kg, this drug did not significantly affect pulse pressure, heart rate, right atrial pressure, aortic blood flow, left ventricular (LV) pressure, LV dP/dt, or myocardial oxygen consumption. The results indicate the SG-75 has desirable characteristics as an antianginal agent.

Citations

Feb 1, 1984·British Journal of Pharmacology·Y AbikoK Sakai
Mar 1, 1995·Cardiovascular Drugs and Therapy·J C Kaski
Feb 1, 1993·Cardiovascular Drugs and Therapy·S Di SommaM de Divitiis
Jan 3, 2001·Anesthesia and Analgesia·K SatohS Joh
Jan 1, 1992·European Journal of Clinical Pharmacology·M MolinaroE Sartirana
Apr 1, 1994·The Journal of Urology·P HedlundK E Andersson
May 16, 2002·Clinical and Experimental Pharmacology & Physiology·Stéphanie Garnier-RaveaudJean Verdetti
Jun 1, 1995·Journal of Anesthesia·Shohei TakedaTeruaki Tomaru
Aug 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·M SakanashiJ Nakasone
Aug 1, 1990·Cardiovascular Drugs and Therapy·M Kinoshita, K Sakai
Jan 1, 1984·European Journal of Clinical Pharmacology·G G BelzG Wagner
Dec 1, 1990·Cardiovascular Drugs and Therapy·K HashimotoM Kinoshita
Dec 23, 2020·Advances in Therapy·Kevin ChengRanil De Silva
Jan 1, 1990·Pharmacology & Therapeutics·G Edwards, A H Weston
Nov 3, 1994·European Journal of Pharmacology·W UchidaT Takenaka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.